Ovarian Carcinoma, Primary Peritoneal Carcinoma
Conditions
Brief summary
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
Detailed description
Patients will be treated with pemetrexed 500 mg/m2 IV and Bevacizumab 15 mg/kg IV every 3 weeks.The patient is treated indefinitely until side effects are deemed severe by the investigator or until progression. Disease progression is measured every 6 weeks using RECIST criteria.
Interventions
DRUGPemetrexed
DRUGBevacizumab
Sponsors
Columbia University
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Recurrent epithelial ovarian or primary peritoneal carcinoma. Histologic confirmation of the primary tumor is required. Patients with borderline tumors are not eligible. * Patients must have measurable disease. Measurable disease is defined as at least one lesion that can be accurately measured in one dimension (longest dimension to be recorded). Each lesion must by \> 20 mm when measured by conventional imaging techniques, including plain radiography, computed tomography and MRI or \> 10 mm when measured by spiral CT. * Patients must have at least one target lesion to assess response by RECIST criteria. Lesions within a previously irradiated field will be considered non-target lesions. * Patients must have a GOG performance status of 0 or 1. * Patients must have the ability to interrupt non-steroidal anti-inflammatory (NSAID) treatment 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed. * Patients must have the ability to take folic acid, vitamin B12 and dexamethasone as described per protocol. * Recovery from effects of recent surgery, radiotherapy or chemotherapy. * Patients should be free of active infection requiring antibiotics. * Any hormonal therapy directed at the tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy (HRT) is permitted. * Any other prior therapy directed at the malignant tumor, including immunologic agents and cytotoxic agents, must be discontinued at least three weeks prior to registration. * Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. This initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment. * Patients must have had one prior regimen containing a taxane compound. Patient may have received first-line treatment either intravenously or intraperitoneally. * Patients must NOT have received prior therapy with pemetrexed or bevacizumab. * Patients may have received a total of \< 2 prior cytotoxic chemotherapy regimens (adjuvant therapy plus one additional regimen). Consolidation or extended therapy as part of first line treatment will be considered as a single regimen. * Bone marrow function: absolute neutrophil count (ANC) greater than or equal to 1,500/ul, equivalent to Common Toxicity Criteria (CTC) grade 1; Platelets greater than or equal to 100,000/ul. * Creatinine clearance must be greater than 45 ml/min. * Hepatic function: bilirubin less than or equal to 1.5 x ULN. AST and alkaline phosphatase less than or equal to 2.5 x ULN. * Neurologic function: neuropathy (sensory and motor) less than or equal to CTC grade 1. * Coagulation: prothrombin time (PT) such that the international normalized ratio (INR) is \< 1.5 (INR may be between 2 and 3 if a patient is on stable dose of therapeutic warfarin) and a PTT \< 1.2 times control. * Patients must have signed informed consent. * Patients must meet pre-entry requirements. * Patients of childbearing potential must have a negative serum pregnancy test prior to study entry, be practicing an effective form of contraception, and cannot be lactating. * Patients may have received prior radiotherapy (to less than 25% of bone marrow), but must start at a Level 1 dose reduction.
Exclusion criteria
* Patients with serious, non-healing wound, ulcer or bone fracture. * Patients with clinically significant cardiovascular disease: * Inadequately controlled hypertension (defined as systolic blood pressure \> 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy. * Unstable angina within 6 months prior to study enrollment. * New York Heart Association (NYHA) grade II or greater congestive heart failure. * Serious cardiac arrhythmia requiring medication. * Grade II or greater peripheral vascular disease. Patients with claudication within 6 months. * History of myocardial infarction within 6 months. * Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels. * Patients with the presence of ascites or other third space fluid which cannot be controlled by drainage. * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of study or anticipation of need for major surgical procedure during the course of the study. * Patients with history or evidence upon physical examination of central nervous system disease, including primary brain tumor, brain metastases, seizure not controlled with standard medical therapy, history of cerebrovascular accident (CVA, stroke), or transient ischemic attack (TIA) or subarachnoid hemorrhage within 6 months of the first date of treatment on this study. * Minor surgical procedures, other than central venous access placement, such as fine needle aspiration or core biopsy within 7 days prior to day 1 of study. * Patients with proteinuria. At baseline patients will undergo a urine protein-creatinine ratio (UPCR) (Appendix IV). Patients with a UPCR \> 1.0 at screening should be excluded. Urine dipstick for proteinuria may also be used. Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Patients whose circumstances do not permit completion of the study or the required follow-up. * Patients who are pregnant or nursing. * Patients under the age of 18. * Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer within the last 5 years or whose previous cancer treatment contraindicates this protocol. * Prior therapy with anti-angiogenic agents or pemetrexed. * Patients with active infection requiring parenteral antibiotics. * History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months. * Partial or complete small or large bowel obstruction demonstrated radiographically within 3 months prior to study. * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study. * Known hypersensitivity to any component of bevacizumab. * Inability to comply with study and/or follow-up procedures. * Life expectancy of less than 12 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | 6 months | PFS = Period from study entry until disease progression, death, or date of last contact |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Distribution of Overall Survival (OS) | Median follow-up was 25.7 months (range 3.0-47.2 months) | OS = observed length of time from entry into the study to death or date of last contact |
| Toxicity Associated With Bevacizumab and Pemetrexed | 6 months | Detailed serious adverse events and other adverse events are shown in the adverse event module of the results. |
| Distribution of Progression-free Survival (PFS) | Median follow-up was 25.7 months (range 3.0-47.2 months) | PFS = Period from study entry until disease progression, death, or date of last contact |
| Gene Expression as Assessed by Illumina cDNA Mediated Annealing, Selection, Extension and Ligation (DASL) Microarray From Paraffin-embedded Tumor Specimens With Response to Pemetrexed and Bevacizumab | 6 months | — |
| Association Between Levels of Thymidylate Synthase, Dihydrofolate Reductase, and Glycinamide Ribonucleotide Formyl Transferase and Ovarian Response to Pemetrexed and Bevacizumab | 6 months | — |
| Frequency of Clinical Response | 6 months | As measured by RECIST criteria |
Countries
United States
Participant flow
Recruitment details
The study was open to participant enrollment on 05/28/2008 and closed to participant enrollment on 11/30/2010.
Participants by arm
| Arm | Count |
|---|---|
| Pemetrexed and Bevacizumab Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle
Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle | 34 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Ineligible | 4 |
Baseline characteristics
| Characteristic | Pemetrexed and Bevacizumab |
|---|---|
| Age, Continuous | 61.5 years |
| Gynecologic Oncology Group (GOG) Performance Status 0 | 22 participants |
| Gynecologic Oncology Group (GOG) Performance Status 1 | 12 participants |
| Histology Endometriod | 2 participants |
| Histology Mixed | 3 participants |
| Histology Other | 5 participants |
| Histology Serous | 24 participants |
| Pathologic diagnosis Fallopian tube | 1 participants |
| Pathologic diagnosis Ovarian | 27 participants |
| Pathologic diagnosis Primary peritoneal | 6 participants |
| Platinum-free interval >12 months | 11 participants |
| Platinum-free interval 6-12 months | 11 participants |
| Platinum-free interval <6 months | 12 participants |
| Prior number of chemotherapy regimens 1 | 20 participants |
| Prior number of chemotherapy regimens 2 | 14 participants |
| Region of Enrollment United States | 34 participants |
| Sex: Female, Male Female | 34 Participants |
| Sex: Female, Male Male | 0 Participants |
| Stage Stage III | 27 participants |
| Stage Stage I/II | 1 participants |
| Stage Stage IV | 6 participants |
| Tumor grade Grade 1 | 3 participants |
| Tumor grade Grade 2 | 1 participants |
| Tumor grade Grade 3 | 30 participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 34 / 34 |
| serious Total, serious adverse events | 5 / 34 |
Outcome results
Primary
Progression-free Survival (PFS)
PFS = Period from study entry until disease progression, death, or date of last contact
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pemetrexed and Bevacizumab | Progression-free Survival (PFS) | 56 percentage of participants |
Secondary
Association Between Levels of Thymidylate Synthase, Dihydrofolate Reductase, and Glycinamide Ribonucleotide Formyl Transferase and Ovarian Response to Pemetrexed and Bevacizumab
Time frame: 6 months
Population: This outcome was not analyzed. Columbia University was to participate in this study but did not. They were to perform the correlative studies.
Secondary
Distribution of Overall Survival (OS)
OS = observed length of time from entry into the study to death or date of last contact
Time frame: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Pemetrexed and Bevacizumab | Distribution of Overall Survival (OS) | Platinum-free interval of <6 months | 16.7 months |
| Pemetrexed and Bevacizumab | Distribution of Overall Survival (OS) | Platinum-free interval of 6-12 months | 24.9 months |
| Pemetrexed and Bevacizumab | Distribution of Overall Survival (OS) | Platinum-free interval of >12 months | 28.0 months |
Secondary
Distribution of Progression-free Survival (PFS)
PFS = Period from study entry until disease progression, death, or date of last contact
Time frame: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Pemetrexed and Bevacizumab | Distribution of Progression-free Survival (PFS) | Platinum-free interval of <6 months | 6.7 months |
| Pemetrexed and Bevacizumab | Distribution of Progression-free Survival (PFS) | Platinum-free interval of 6-12 months | 4.7 months |
| Pemetrexed and Bevacizumab | Distribution of Progression-free Survival (PFS) | Platinum-free interval of >12 months | 16.8 months |
Secondary
Frequency of Clinical Response
As measured by RECIST criteria
Time frame: 6 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pemetrexed and Bevacizumab | Frequency of Clinical Response | Complete response | 0 participants |
| Pemetrexed and Bevacizumab | Frequency of Clinical Response | Partial response | 14 participants |
| Pemetrexed and Bevacizumab | Frequency of Clinical Response | Stable disease | 18 participants |
| Pemetrexed and Bevacizumab | Frequency of Clinical Response | Progressive disease | 2 participants |
Secondary
Gene Expression as Assessed by Illumina cDNA Mediated Annealing, Selection, Extension and Ligation (DASL) Microarray From Paraffin-embedded Tumor Specimens With Response to Pemetrexed and Bevacizumab
Time frame: 6 months
Population: This outcome was not analyzed. Columbia University was to participate in this study but did not. They were to perform the correlative studies.
Secondary
Toxicity Associated With Bevacizumab and Pemetrexed
Detailed serious adverse events and other adverse events are shown in the adverse event module of the results.
Time frame: 6 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pemetrexed and Bevacizumab | Toxicity Associated With Bevacizumab and Pemetrexed | Grade 3/4 hematologic toxicity | 53 percentage of participants |
| Pemetrexed and Bevacizumab | Toxicity Associated With Bevacizumab and Pemetrexed | Most common non-hematologic toxicity - fatigue | 94 percentage of participants |
| Pemetrexed and Bevacizumab | Toxicity Associated With Bevacizumab and Pemetrexed | Grade 3 renal toxicity | 6 percentage of participants |
| Pemetrexed and Bevacizumab | Toxicity Associated With Bevacizumab and Pemetrexed | Gastrointestinal toxicity | 91 percentage of participants |
| Pemetrexed and Bevacizumab | Toxicity Associated With Bevacizumab and Pemetrexed | Subsequently developed hematologic malignancies | 6 percentage of participants |
Post Hoc
CA-125 Response
A CA-125 response was defined as at least a 50% reduction in CA-125 levels from a pretreatment sample following guidelines described by the Gynecological Cancer Intergroup.
Time frame: 6 months
Population: 7 participants were not evauable by CA-125 criteria.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pemetrexed and Bevacizumab | CA-125 Response | 50% CA-125 response | 17 participants |
| Pemetrexed and Bevacizumab | CA-125 Response | 75% CA-125 response | 8 participants |
| Pemetrexed and Bevacizumab | CA-125 Response | No CA-125 response | 2 participants |
Post Hoc
Overall Response Rate
Overall response rate = complete response + partial response Complete response = disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response = at least a 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be non unequivocal progression of non-target lesions and no new lesions.
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pemetrexed and Bevacizumab | Overall Response Rate | 41 percentage of participants |
Post Hoc
Overall Survival (OS)
OS = observed length of time from entry into the study to death or date of last contact
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pemetrexed and Bevacizumab | Overall Survival (OS) | 79 percentage of participants |
Post Hoc
Overall Survival (OS)
OS = observed length of time from entry into the study to death or date of last contact
Time frame: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Pemetrexed and Bevacizumab | Overall Survival (OS) | 25.7 months |
Post Hoc
Progression-free Survival (PFS)
PFS = Period from study entry until disease progression, death, or date of last contact
Time frame: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Pemetrexed and Bevacizumab | Progression-free Survival (PFS) | 7.9 months |